S03 E16: Pharma review of the year 2022
EMJ GOLD: Pharma news, views and analysis
00:00
Access and Inequity - The Biggest Challenge
FDA recently approved the world's first gene therapy for hemophilia B. With a list price of $3.5 million, it would make it the most expensive single-use gene therapy in US history. But if you consider that the current lifetime cost of treating people with moderate to severe hemophili B connects seed 20 million per person,. You can see it's just about your perspective, which time horizon for how much money and what is the gain. Even when patients do get access to medicines, more than a million patients in the UK are missing out on life-changing treatments.
Play episode from 03:41
Transcript
